These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 12796471

  • 1. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase.
    Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H.
    J Exp Med; 2003 Jun 16; 197(12):1635-44. PubMed ID: 12796471
    [Abstract] [Full Text] [Related]

  • 2. DNA vaccination with glutamic acid decarboxylase (GAD) generates a strong humoral immune response in BALB/c, C57BL/6, and in diabetes-prone NOD mice.
    Wiest-Ladenburger U, Fortnagel A, Richter W, Reimann J, Boehm BO.
    Horm Metab Res; 1998 Oct 16; 30(10):605-9. PubMed ID: 9851666
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta?
    Song L, Wang J, Wang R, Yu M, Sun Y, Han G, Li Y, Qian J, Scott DW, Kang Y, Soukhareva N, Shen B.
    Gene Ther; 2004 Oct 16; 11(20):1487-96. PubMed ID: 15343360
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.
    Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO.
    Nature; 1993 Nov 04; 366(6450):72-5. PubMed ID: 8232539
    [Abstract] [Full Text] [Related]

  • 7. Natural history of humoral immunity to glutamic acid decarboxylase in non-obese diabetic (NOD) mice.
    De Aizpurua HJ, French MB, Chosich N, Harrison LC.
    J Autoimmun; 1994 Oct 04; 7(5):643-53. PubMed ID: 7840856
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation.
    Murray JS, Oney S, Page JE, Kratochvil-Stava A, Hu Y, Makagiansar IT, Brown JC, Kobayashi N, Siahaan TJ.
    Chem Biol Drug Des; 2007 Sep 04; 70(3):227-36. PubMed ID: 17718717
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles.
    Han G, Wang R, Chen G, Wang J, Xu R, Feng J, Yu M, Wu X, Qian J, Shen B, Li Y.
    Immunol Lett; 2008 Jan 29; 115(2):110-6. PubMed ID: 18045698
    [Abstract] [Full Text] [Related]

  • 18. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes.
    Jaeckel E, Lipes MA, von Boehmer H.
    Nat Immunol; 2004 Oct 29; 5(10):1028-35. PubMed ID: 15378058
    [Abstract] [Full Text] [Related]

  • 19. [Development of rAAV2-GAD-Ig for IDDM gene therapy].
    Wang RX, Wang JA, Song L, Han GC, Shen BF, Wu XB, Li Y.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan 29; 21(1):24-8. PubMed ID: 15629077
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.